GET DAILY SIGNALSHeartBeam (BEAT) Narrows Q3 Loss to $3.0 Million With 35% Lower Expenses
Key Takeaways
- HeartBeam reported a third-quarter net loss of $3.0 million, or $0.05 per share, versus a loss of $5.3 million, or $0.15 per share, a year earlier.
- The result beat the consensus estimate of a $0.09 per-share loss, though revenue remained effectively zero against a roughly $76,500 forecast.
- Operating expenses fell about 35% year over year to $3.5 million, driving the improvement rather than any meaningful top-line contribution.
- Net cash used in operations was $2.6 million, down 23% sequentially, and the company reduced its full-year 2026 cash outflow guidance to $12.0 million–$12.5 million.
- Regulatory momentum accelerated, including FDA Breakthrough Device Designation and alignment on a 510(k) pathway for heart attack assessment.
- For deeper coverage of this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Looking for data-driven trade ideas? Discover Trending AI Robots for automated market insights.
Why the Quarter Matters for HeartBeam
HeartBeam (BEAT) remains a development-stage medical technology company developing a cable-free device that records electrocardiogram signals in three dimensions and converts them into a standard 12-lead ECG. With no meaningful commercial revenue yet, quarterly results are evaluated primarily on cash management, regulatory progress, and clinical advancement. The third quarter of 2026 stood out because management had shifted most resources toward heart attack assessment, and I was watching to see whether that focus would produce lower spending, an extended cash runway, and clearer regulatory signals ahead of a key U.S. study.
Third-Quarter Results in Detail
For the quarter ended September 30, 2026, HeartBeam (BEAT) posted a net loss of $3.0 million, or $0.05 per share, compared with a net loss of $5.3 million, or $0.15 per share, in the same period a year ago. The figure came in better than the consensus estimate of a $0.09 per-share loss. Revenue stayed essentially at zero, versus the modest consensus projection of roughly $76,500, consistent with the pre-commercial stage.
Most of the improvement came from the expense side. Total operating expenses dropped about 35% year over year to $3.5 million. Research and development expense fell to roughly $2.1 million while selling, general, and administrative expense declined to about $1.3 million. Net cash used in operating activities was $2.6 million, down 23% from the prior quarter and 18% from a year earlier. Cash and cash equivalents stood at $6.1 million at quarter-end and reached approximately $10.1 million on a pro forma basis after roughly $4.0 million in net proceeds from an at-the-market equity program in the fourth quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Shares closed the regular session down about 1.8% at $0.4037 before gaining roughly 2.8% in after-hours trading to around $0.415. The reaction was measured. The narrower loss and reduced cash burn drew positive attention, yet the stock remains well below its 52-week high of $4.00 and continues to trade at penny-stock levels. Sentiment before the report had been cautious amid the Nasdaq minimum bid price notice and ongoing capital requirements for the clinical program. Investors appear to be giving credit for the improved cost structure and regulatory clarity while still weighing financing and commercialization risks.
Outlook and Milestones Ahead
Management tightened guidance, now expecting baseline fourth-quarter operating cash outflow below $2.5 million and full-year 2026 net operating cash outflow between $12.0 million and $12.5 million, a reduction from earlier targets. The company indicated its cash runway now extends further into 2027, though spending could rise if the timing of the pivotal study accelerates.
Regulatory developments represent the primary catalyst. In recent weeks HeartBeam (BEAT) received FDA Breakthrough Device Designation, joined the FDA’s Total Product Life Cycle Advisory Program, and reached alignment with the agency on a 510(k) submission pathway for heart attack assessment. The company also finished enrollment in its HEADSTART-ACS study ahead of schedule and presented positive ALIGN-ACS pilot study results at TCT, demonstrating higher specificity than a standard 12-lead ECG.
Looking forward, investors should track the final design and start of the U.S. pivotal study targeted for the first quarter of 2027, along with updates on reimbursement, Nasdaq compliance, and additional ATM raises. Because HeartBeam (BEAT) is still pre-revenue, progress on these milestones will likely shape the next phase of attention more than quarterly sales figures.
Exploring Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating development-stage names like this one. The tool lets me quickly filter stocks by industry, technical patterns, fundamentals, and AI signals, which helps surface comparable ideas and spot broader market context without spending hours on manual work. It has become a regular part of how I cross-check positioning and identify potential trade ideas alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BEAT in +1.31% Uptrend, growing for three consecutive days on November 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BEAT advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAT as a result. In 78 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for BEAT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
BEAT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BEAT crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.770) is normal, around the industry mean (4.477). P/E Ratio (-0.788) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a wireless medical technology company, which focuses on the delivery of health information
Industry ServicestotheHealthIndustry
Advertisement